摘要
目的探讨血速升颗粒联合环孢素(cyclosporine,Cs)A治疗非重型再生障碍性贫血(non-severe aplastic anemia,NSAA)的效果和对GATA结合蛋白(GATA binding protein,GATA)-3、粒细胞集落刺激因子(granulocyte colony stimulating factor,G-CSF)及早期造血恢复的影响。方法选择2021年6月至2023年1月我院接诊的NSAA患者46例,以随机数表法分为观察组(n=24)和对照组(n=22)。对照组接受CsA治疗,观察组加用血速升颗粒治疗。比较两组临床疗效、GATA-3、G-CSF、血红蛋白(hemoglobin,Hb)、红细胞(red blood cells,RBC)、血细胞比容(hematocrit,HCT)、细胞免疫水平变化及不良反应发生情况。结果观察组治疗总有效率高于对照组,但差异无统计学意义(75.00%vs 54.55%,P>0.05)。观察组GATA-3、白细胞分化抗原(cluster of differentiation,CD)4+、CD4+/CD8+水平低于对照组(P<0.05),G-CSF、Hb、RBC、HCT、CD8+水平高于对照组(P<0.05)。观察组较对照组不良反应少,但差异无统计学意义(25.00%vs 36.36%,P>0.05)。结论血速升颗粒联合CsA可一定程度改善NSAA患者GATA-3、G-CSF及早期造血情况。
Objective To investigate the effects of Xuesuisheng granule combined with cyclosporine(Cs)A on nonsevere aplastic anemia(NSAA)and its effects on GATA binding protein(GATA)-3,granulocyte colony stimulating factor(G-CSF)and early hematopoietic recovery.Methods Forty-six patients with NSAA admitted to our hospital from June 2021 to January 2023 were selected and divided into observation group(n=24)and control group(n=22)by random number table.The control group was treated with CsA,and the observation group was treated with Xuesuisheng granules.The clinical efficacy,changes in GATA-3,G-CSF,hemoglobin(Hb),red blood cells(RBC),hematocrit(HCT),cellular immune function and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,but the difference was not statistically significant(54.55%vs 75.00%,P>0.05).Compared with the control group,the levels of GATA-3,cluster of differentiation CD4+and CD4+/CD8+in the observation group were decreased(P<0.05),while the levels of G-CSF,Hb,RBC,HCT and CD8+were increased(P<0.05).The adverse reactions in the observation group were less than those in the control group,but the difference was not statistically significant(36.36%vs 25.00%,P>0.05).Conclusion Xuesuisheng granule combined with CsA can improve GATA-3,G-CSF and early hematopoiesis in patients with NSAA to a certain extent.
作者
李三喜
颜保松
徐玲
邹秀敏
张正义
LI Sanxi;YAN Baosong;XU Ling;ZOU Xiumin;ZHANG Zhengyi(Clinical Laboratory,928 Hospital of the PLA Joint Logistic Support Force,Haikou 571159,Hainan Province,China;Department of Hematology,928 Hospital of the PLA Joint Logistic Support Force,Haikou 571159,Hainan Province,China)
出处
《世界临床药物》
CAS
2023年第11期1179-1184,共6页
World Clinical Drug
